Related Experiment Video
Updated: Jun 15, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
A Case of Scrofuloderma in a Patient on JAK Inhibitor Treatment for Rheumatoid Arthritis
Tomomichi Shimizu1, Ayako Hirota, Nobuhiro Takahashi
1Department of Dermatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. shimizu.t@tokai.ac.jp.
A patient on baricitinib developed tuberculosis (Mycobacterium tuberculosis), presenting as a subcutaneous abscess and lymphadenopathy. Prompt antitubercular treatment led to complete resolution, highlighting a rare but serious adverse event of JAK inhibitor therapy.
Area of Science:
- Rheumatology
- Infectious Diseases
- Pharmacology
Background:
- Baricitinib is a Janus kinase (JAK) inhibitor used for rheumatoid arthritis.
- Immunosuppression from JAK inhibitors can increase the risk of opportunistic infections, including tuberculosis.
Related Concept Videos
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

